ICON-1

BIOLOGICAL2 trials

Sponsors

Iconic Therapeutics, Inc.

Conditions

Choroid NeoplasmChoroidal NeovascularizationUveal MelanomaWet Macular Degeneration

Phase 1

Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

CompletedNCT02771340

Iconic Therapeutics, Inc.Choroid Neoplasm, Uveal Melanoma

Start: 2016-05-31End: 2017-09-30Updated: 2020-10-01

Phase 2

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

TerminatedNCT03452527

Iconic Therapeutics, Inc.Choroidal Neovascularization, Wet Macular Degeneration

Start: 2018-03-26End: 2019-04-25Updated: 2021-04-13